FIA
IMDX

FNY Investment Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

FNY Investment Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
182,561
-64,860
-26% -$320K 0.39% 63
2026
Q1 		$811K Buy
247,421
+206,837
+510% +$1.2M 0.35% 71
2025
Q4 		$304K Sell
40,584
-12,493
-24% -$70.5K 0.09% 185
2025
Q3 		$176K Buy
53,077
+28,427
+115% +$80.2K 0.06% 291
2025
Q2 		$74K Sell
24,650
-14,522
-37% -$43.9K 0.03% 336
2025
Q1 		$119K Sell
39,172
-10,205
-21% -$27.6K 0.07% 198
2024
Q4 		$117K Buy
49,377
+6,481
+15% +$17.6K 0.06% 252
2024
Q3 		$122K Buy
42,896
+19,242
+81% +$59.7K 0.06% 212
2024
Q2 		$69K Buy
+23,654
New +$65K 0.05% 218

Other funds holding IMDX

PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

FNY Investment Advisers's IMDX Position: Q2 2026 in Review

FNY Investment Advisers reduced its Insight Molecular Diagnostics (IMDX) stake by 26% in Q2 2026, selling an estimated $320K and leaving 182,561 shares worth $1.08M. The position accounts for 0.39% of the portfolio, ranked #63.

FNY Investment Advisers first reported a position in IMDX in Q2 2024 and has held it in 9 quarters since. 3 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • FNY Investment Advisers held 182,561 shares of Insight Molecular Diagnostics worth $1.08M as of Q2 2026.
  • FNY Investment Advisers sold 64,860 Insight Molecular Diagnostics shares in Q2 2026, an estimated $320K.
  • Insight Molecular Diagnostics made up 0.39% of FNY Investment Advisers's portfolio in Q2 2026, its #63 holding.
  • FNY Investment Advisers first reported a position in Insight Molecular Diagnostics in Q2 2024 and has held it in 9 quarters since.
  • 3 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.